Drug Type Exosomes |
Synonyms Exosomes From Human Mesenchymal Stem Cells(Vitti Labs), VL-PX10 |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 2 | US | 30 Nov 2022 | |
COVID-19 respiratory infection | Phase 2 | US | 30 Nov 2022 | |
Pulmonary Fibrosis | Phase 2 | US | 30 Nov 2022 | |
Post Acute COVID 19 Syndrome | Phase 2 | US | 30 Jan 2022 | |
Respiratory Distress Syndrome, Acute | Phase 1 | US | 20 Mar 2025 | |
Diminished ovarian reserve | Phase 1 | US | 06 Oct 2023 | |
Menopause, Premature | Phase 1 | US | 06 Oct 2023 | |
Primary Ovarian Insufficiency | Phase 1 | US | 18 Oct 2022 | |
Brain Injuries, Traumatic | IND Application | US | 30 Jan 2022 | |
Polycystic Ovary Syndrome | IND Application | US | 30 Jan 2022 |
Phase 2 | Advanced breast cancer First line | 26 | vwgcqypaam(ajykzwvibv) = qptcpzhmxw ctbjobzlfu (vwhsrilnms ) View more | - | 01 Jun 2005 |